Apellis Pharmaceuticals Inc Earnings

Apellis Pharmaceuticals Inc’s revenue fell -3.21% since last year same period to $166.8Mn in the Q1 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -21.52% fall in its revenue since last 3-months.

Apellis Pharmaceuticals Inc’s net profit fell -38.84% since last year same period to $-92.23Mn in the Q1 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -153.69% fall in its net profits since last 3-months.

Apellis Pharmaceuticals Inc’s net profit margin fell -43.45% since last year same period to -55.29% in the Q1 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -223.25% fall in its net profit margins since last 3-months.

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.15 - a 69.82% jump from last quarter’s estimates.

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.15.

Apellis Pharmaceuticals Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Apellis Pharmaceuticals Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.